Eterna Therapeutics - ERNA Earnings per share for the last twelve months

Official company branding of eternatx.com (ERNA)

The mRNA platform market for blood therapies possesses colossal growth potential. The TTM EPS trend for Eterna Therapeutics (ERNA) on the GURU.Markets terminal linear chart contains current data, where the indicator level stands at -17.05. Eterna Therapeutics relies on laboratory partnerships and patent acquisitions; however, the high cost of cellular engineering and the risk of early-stage test failures create financial instability.

ERNA Eterna Therapeutics Inc Net earnings per one share for the last twelve months (04/28/2023 - 11/16/2026)

Analytical breakdowns and data insights for company eternatx.com (ERNA)

- current quotes and average value forecast:
Summary company analytics:eternatx.com (ERNA)
Manufactured products of Eterna Therapeutics

The metric is calculated as the ratio of total annual net income to the number of common shares. This metric determines the actual efficiency of capital allocation and the sensitivity of profit to operating expenses. For Eterna Therapeutics, which invests in mRNA therapy and cellular engineering, this reflects the cost of R&D developments. The current value of -17.05 demonstrates the business's current profitability. Analyzing the rolling 12-month earnings per share allows for the early identification of liquidity shortage risks.